Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODULAATE Study
2024-511164-92-00Phase 3Completed
- Sponsor
- CSL Behring
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Alpha-1 Antitrypsin (Respreeza) with Placebo (albumin solution) (2 arms). Primary endpoint: Time to Grade II-IV acute graft-versus-host disease or death. Started May 2019; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2024-511164-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511164-92-00.